Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 9/20 | 0.75 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.75 |
| ▸ | BRD4 | O60885 | 10/20 | 0.71 |
| ▸ | JAK2 | O60674 | 6/20 | 0.66 |
| ▸ | JAK3 | P52333 | 5/20 | 0.61 |
| ▸ | TYK2 | P29597 | 3/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.61 |
| ▸ | RET | P07949 | 2/20 | 0.61 |
| ▸ | WEE1 | P30291 | 2/20 | 0.61 |
| ▸ | FLT3 | P36888 | 2/20 | 0.61 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25382228 | 1.00 | JAK1 (0.75) | JAK1HDAC1BRD4JAK2JAK3 | |
| SCHEMBL30565200 | 0.95 | JAK1 (0.81) | JAK1HDAC1BRD4JAK2JAK3 | |
| SCHEMBL25383521 | 0.95 | JAK1 (0.81) | JAK1HDAC1BRD4JAK2JAK3 | |
| SCHEMBL28657345 | 0.90 | BRD4 (0.77) | JAK1HDAC1BRD4JAK2JAK3 | |
| SCHEMBL31163062 | 0.89 | JAK1 (0.76) | JAK1HDAC1BRD4JAK2JAK3 | |
| SCHEMBL31163090 | 0.89 | JAK1 (0.72) | JAK1HDAC1BRD4JAK2JAK3 | |
| SCHEMBL31163048 | 0.88 | JAK1 (0.72) | JAK1HDAC1BRD4JAK2JAK3 | |
| SCHEMBL31163082 | 0.88 | JAK1 (0.72) | JAK1HDAC1BRD4JAK2JAK3 | |
| SCHEMBL25380756 | 0.87 | JAK1 (0.71) | JAK1HDAC1BRD4JAK2JAK3 | |
| SCHEMBL31163066 | 0.87 | JAK1 (0.73) | JAK1HDAC1BRD4JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673149-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. | 2025-06-12 | — | — | US | disclosed |
| EP-4486348-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024179699-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | BASH BIOTECH INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2023166153-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | BASH BIOTECH INC (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | RCC2, GLS, VHL | JAK1 2901/4885HDAC1 128/4885BRD4 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.